Lepu Biopharma Co (HKSE:02157) Payments of Debt: HK$-613 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02157 Lepu Biopharma Co Ltd HKSE:02157
45 GF Score
Price HK$3.99
GF Value HK$16.98
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Lepu Biopharma Co Payments of Debt?

Lepu Biopharma Co HKSE:02157 +6.69% 45 Payments of Debt is HK$-613 Mil as of Dec. 2025. GuruFocus rates HKSE:02157 with a GF Score™ of 45/100 and a GF Value™ of HK$16.98 (Possible Value Trap). The stock has 6 warning signs investors should review.

Lepu Biopharma Co's Payments of Debt for the six months ended in Dec. 2025 was HK$-300 Mil.

Lepu Biopharma Co's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-613 Mil.

Lepu Biopharma Co Payments of Debt Related Terms

Lepu Biopharma Co Payments of Debt Historical Data

* Premium members only.

The historical data trend for Lepu Biopharma Co's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lepu Biopharma Co Payments of Debt Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -0.61 -90.43 -393.00 -517.17 -616.42

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -280.13 -239.35 -312.76 -300.32 0.00
HKSE:02157
45GF Score
Lepu Biopharma Co Ltd HKSE:02157
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lepu Biopharma Co Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-613 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of HK$-613 Mil mean?
Lepu Biopharma Co (HKSE:02157) has a Payments of Debt of HK$-613 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lepu Biopharma Co and its competitors.
Is Lepu Biopharma Co's Payments of Debt too high?
Lepu Biopharma Co's current Payments of Debt is HK$-613 Mil. Overall, Lepu Biopharma Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's Payments of Debt compare to VRTX and REGN?
Lepu Biopharma Co's Payments of Debt of HK$-613 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lepu Biopharma Co and its competitors. Lepu Biopharma Co's current Payments of Debt is HK$-613 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.98, compared to a current price of HK$3.99 — trading 76.5% below its estimated fair value. The current Payments of Debt is HK$-613 Mil. Lepu Biopharma Co's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current Payments of Debt is HK$-613 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?

Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued. The current stock price of HK$3.99 is trading 76.5% below its estimated GF Value™ of HK$16.98. GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.

Key valuation signals for HKSE:02157:

  • Payments of Debt: HK$-613 Mil
  • GF Value™: HK$16.98 vs. price of HK$3.99 (76.5% below fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lepu Biopharma Co Business Description

Address Lianheng Road, Block 4, No. 651, Minhang District, Shanghai, CHN, 201112
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
45GF Score

Get the complete analysis for HKSE:02157

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.99
Price
HK$16.98
GF Value